Page 1,618«..1020..1,6171,6181,6191,620..1,6301,640..»

SUNY Adirondack to offer program on diabetes treatment – Glens Falls Post-Star

Posted: April 4, 2017 at 1:46 am

QUEENSBURY The SUNY Adirondack Nursing Alumni Speakers Series will feature the program What Nurses Need to Know: Recent Advances in the Treatment and Management of the Diabetic Patient at 5 p.m. Wednesday.

The program will be held in Room 128 of the J. Buckley Bryan Jr. Regional Higher Education Center.

The event will provide up-to-date information regarding care of patients with diabetes, including categories of drugs on the market, technologies for diabetics and case management, including diet, hospital discharge and specialty referral.

Presenters include Dr. Christine Alexander-Decker, from the Center of Endocrinology and Diabetes of Saratoga Hospital; and Abby Bayer and Kat Christensen, both graduates of SUNY Adirondacks nursing program.

Free 1.5 hours of CEU credit will be offered to all attendees.

The program is free and open to the public. The information provided will be geared toward nurses and nursing students.

For more information, contact Jill Vogel at the SUNY Adirondack Foundation at 743.2244.

Visit link:
SUNY Adirondack to offer program on diabetes treatment - Glens Falls Post-Star

Posted in Diabetes | Comments Off on SUNY Adirondack to offer program on diabetes treatment – Glens Falls Post-Star

After family tragedy, Lions’ Alex Carter fights for diabetes research funding – ESPN (blog)

Posted: April 4, 2017 at 1:46 am

Lions cornerback Alex Carter (far left) met with U.S. Sen. Gary Peters (D-Michigan) in Washington last week about diabetes research funding.

Alex Carter wanted to be an advocate for years. It was one of the things he made clear when he entered the NFL three seasons ago. He just didnt know his first big venture into trying to help cure diabetes would come through an email.

Thats exactly what happened to the Detroit Lions cornerback a few weeks ago. The NFLPA reached out looking for players who might be interested to going to Washington to help advocate for the continued funding of diabetes research. Carter saw the email. He reached out to his family.

They told him, Youre ridiculous if you dont do it.

Thats how Carter ended up meeting with staffs for U.S. Sens. Ron Johnson (R-Wisconsin), Tammy Baldwin (D-Wisconsin) and Gary Peters (D-Michigan) for about a half-hour each last week. In the meetings, Carter, Indianapolis Colts safety Stefan McClure and members of the American Diabetes Association shared their stories as part of the 2017 Call to Congress Advocacy Day. They explained why the federal government needed to continue funding for diabetes research. They also pushed to help lower the cost of insulin. Carter said there were 40 NFL players advocating for diabetes funding last week.

This has been a personal issue for Carter for years. His sister, Cameron, died of complications from Type 1 diabetes. at age 14. Another sister, Madison, also has Type 1 diabetes. She graduated from college early, Carter said, in part because she knew she would eventually need to afford the insulin that helps keep her alive on her own without their parents insurance. Other family members, Carter said, suffer from Type 2 diabetes.

Cameron died the morning of Feb. 21, 2012, of complications from Type 1 diabetes. Carters mother, Renee, found Cameron lying on the floor in her room. She screamed and Carter came running into the room, thinking they saw a spider. He saw his sister on the floor and thought she had passed out.

Carter hugged his dad. Saw him crying. Then he left to pick up his other sisters from school and didnt know how serious it was even as he went to the hospital.

Me and my sister walked up and they were like, She didnt make it," Carter told ESPN in 2015. I kind of broke down. Ran away. It was pretty tough, just out the door. I couldnt believe it. Started crying. Then I got myself back together and came in.

My parents were like, 'You have two young sisters still; youve got to be a man and youve got to show them you can keep them together still.'

Camerons death caused Carter to rethink his decision to go to Stanford -- but he eventually chose to go. Her death also put diabetes at the forefront of issues he began to learn and care about.

Thats the story Carter told last week in Washington.

They really just wanted all these NFL players to come in and pretty much share their personal testimony of how their families are affected by diabetes and why its so important to continue funding research, Carter said. Thats pretty much the gist of everything. We were just there as players advocating to the government, to Congress, that this means a lot.

So many lives are affected by it. Me personally, Ive already lost somebody in my family because of diabetes and we cant cut funds, pretty much.

The Center for Disease Control estimated last year that more than 29 million Americans have diabetes and 86 million have pre-diabetes, which adds to someones risk of turning into Type 2 diabetes. The CDC says diabetes was the seventh-leading cause of death in the United States in 2013 and more than 20 percent of health care spending is for people with diagnosed diabetes.

The difference between Type 1 diabetes and Type 2 diabetes is with Type 1, people dont make any (or enough) insulin. In Type 2, peoples bodies either have too little insulin or are unable to use insulin properly. The CDC estimates that 90 to 95 percent of diabetes cases in the United States are Type 2 diabetes.

The cost of insulin, which is used to regulate and treat diabetes, has increased from $231.48 per patient per year in 2002 to $736.09 in 2013, according to a study published in the Journal of the American Medical Association last year. In the same study, the price of insulin per millimeter increased 197 percent.

This is part of what Carter is trying to fight to keep the costs of insulin down while making sure funding to help find a cure for the disease remains.

Its even more personal for Carter because while he does not present any symptoms of diabetes, he knows that because of his family history, he could in the future.

When I spoke to Congress and I spoke to people, I said I was honestly surprised that I dont have it personally, Carter said. Im surprised. But Im also preparing myself for life if that ever does happen, you know.

For now, hes doing what he can to get more involved. He believes there was headway made in both his conversations on Capitol Hill and those of his NFL peers who met with other members of Congress. Carter also spoke to members of the American Diabetes Association on Friday, telling his story.

Before last week, Carter had mostly participated in walks to help raise awareness and funds for diabetes research and awareness. Last week was a larger step for him to become more involved.

Im just seeing what doors open, Carter said. Getting more involved with the ADA, thats definitely a path Im going down. Whatever doors open in that direction, Ill do.

Speaking engagements, getting my voice out there, explaining my passion and my mission.

Original post:
After family tragedy, Lions' Alex Carter fights for diabetes research funding - ESPN (blog)

Posted in Diabetes | Comments Off on After family tragedy, Lions’ Alex Carter fights for diabetes research funding – ESPN (blog)

Plants studied as tissue substitute – Arkansas Online

Posted: April 3, 2017 at 6:48 am

JONESBORO -- To most who look inside the refrigerator in a third-floor lab of the Arkansas Biosciences Institute on the Arkansas State University campus, the plastic containers of spinach and other leafy vegetables that line the shelves look like lab workers' lunches.

But to Fabricio Medina-Bolivar, a professor of metabolic engineering at ASU, they look like the future of health care.

Medina-Bolivar and a team of researchers with the Worcester Polytechnic Institute in Worcester, Mass., and the University of Wisconsin at Madison are working together to create vascular networks for heart patients out of leaves and roots.

"The vascular system of the heart is similar to plants," said Medina-Bolivar, who started at ASU in 2005. "We began talking and said, 'Let's see what nature is doing.'"

Representatives from the three universities began brainstorming in 2014 and met at the Arkansas Biosciences Institute in Jonesboro in early 2015.

They liked what they saw, Medina-Bolivar said.

"They were doing stem cell research at the University of Wisconsin," he said. "We wondered if we could really use plant cells for human tissues. We used the same approach with plants."

The team focuses primarily on spinach leaves as the "scaffolds" in which to transplant human cells. The group has already created a replica heart on a spinach leaf by transplanting human heart cells into the plant. A video that the team recently released shows a tiny network of veins leading to the beating "heart."

Researchers flowed fluids and "microbeads" similar in size to human blood cells through the spinach's created vascular system. They also seeded the spinach veins with human cells that line blood vessels.

They also have removed cells from parsley, sweet wormwood and hairy roots of peanuts.

Medina-Bolivar said the growth of human cells in plants also can be used for developing heart muscle, and vascular columns of wood may be useful in bone engineering.

"We have a lot of work to do, but so far this is very promising," Glenn Gaudette, a professor of biomedical engineering at the Worcester Polytechnic Institute, said in a news release about the process. "Adopting abundant plants that farmers have been cultivating for thousands of years for use in tissue engineering could solve a host of problems limiting the field."

Joshua Gershlak, a student of Gaudette's, said in the news release that the stem of a spinach leaf reminded him of an aorta.

"So I thought, 'Let's perfuse right through the stem,'" he said. "We weren't sure it would work, but it turned out to be pretty easy and replicable."

It may sound like the fodder of campy science-fiction films in which mad scientists try to create humans out of plants, but it's working.

"This is incredible," Medina-Bolivar said. "Something like this sounds crazy. This opens the possibility of doing things people never thought of before."

As a youngster growing up in Peru, Medina-Bolivar was curious about how plants were often used for medical remedies when pharmaceutical medicines were not available.

"There was always a plant to be used for something," he said.

He earned a bachelor's degree in biology in Lima, Peru, in 1982, and later a doctorate in plant physiology at Pennsylvania State University.

The research group will meet again next Monday to discuss its next step. The researchers also are seeking millions in grant money, Medina-Bolivar said. They will look at other plants to determine whether they can be used to grow human tissue, he said, but they are still years away from testing in humans.

"This is a whole new venue," he said. "We can repair damaged hearts with plants. This is amazing."

State Desk on 04/03/2017

Visit link:
Plants studied as tissue substitute - Arkansas Online

Posted in Arkansas Stem Cells | Comments Off on Plants studied as tissue substitute – Arkansas Online

Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non … – Business Wire (press release)

Posted: April 3, 2017 at 6:47 am

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2017 American Association for Cancer Research Annual Meeting (AACR) that is currently taking place in Washington, D.C. The presentation entitled, Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 basket study, was presented as a plenary session by David Hyman, M.D., Director of Developmental Therapeutics at Memorial Sloan Kettering Cancer Center (MSK), and principal investigator of the trial.

The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study to evaluate the safety and efficacy of PB272 administered daily to patients who have solid tumors with activating HER2 or HER3 mutations. All patients received loperamide (16 mg per day initially) prophylactically for the first cycle of treatment in order to reduce the neratinib-related diarrhea.

Included in the presentation were data on 141 patients enrolled in the neratinib monotherapy arm of the trial, including 124 patients with HER2 mutations and 17 patients with HER3 mutations. This included patients with 21 unique tumor types, with the most common being breast, lung, bladder and colorectal cancer. There were also 30 distinct HER2 and 12 distinct HER3 mutations observed among these patients, with the most frequent HER2 variants involving S310, L755, A755_G776insYVMA and V777.

In the HER2-mutant cohort, clinical responses were observed in tumors with S310, L755, V777, P780_Y781insGSP and A775_G776insYVMA mutations. When stratified by tumor type, responses were observed in patients with breast, cervical, biliary, salivary and non-small-cell lung cancers, which led to cohort expansions in these tumor types. No activity was observed in the HER3-mutant cohort. A more detailed presentation of the data is presented in Table 1 below and a copy of the full presentation is available on the Puma Biotechnology website.

HER2mut

HER2mut

HER2mut

HER2mut

HER2mut

HER2mut

HER3mut

Lung

(95% CI)

rate, n (%)

(95% CI)

20.1

(95% CI)

(0.5--NA)

The neratinib safety profile observed in the SUMMIT study is consistent with that observed previously in metastatic patients with HER2 amplified tumors. With anti-diarrheal prophylaxis and management, diarrhea was not a treatment-limiting side effect in SUMMIT. The interim safety results of the study showed that the most frequently observed adverse event was diarrhea. For the 141 patients enrolled in the neratinib monotherapy arm with safety data available, 31 patients (22%) reported grade 3 diarrhea. The median duration of grade 3 diarrhea for those patients was 2 days. 4 patients (2.8%) permanently discontinued neratinib due to diarrhea and 21 patients (14.9%) temporarily discontinued neratinib due to diarrhea and then restarted after the diarrhea subsided.

Dr. David Hyman stated, "Neratinib showed signs of clinical activity in several of the cohorts in the SUMMIT trial. The safety profile of the drug was manageable and the diarrhea was not treatment-limiting with appropriate prophylaxis and management. We look forward to completing enrollment in the ongoing cohorts in the study and continuing to utilize the basket trial design to explore possible treatment options for these select patient populations.

"The basket-trial design we are utilizing for SUMMIT is enabling us to evaluate the clinical potential of neratinib in patients with specific mutation-types rather than limiting exploration to one tumor type at a time. It is an efficient approach that is generating clinically meaningful information to guide targeted therapy across a broad spectrum of tumor types with HER mutations, including in patients with rare tumors who may not otherwise have access to investigational therapies, said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. We are very pleased with the preliminary activity seen with neratinib in the SUMMIT trial. We look forward to advancing this targeted compound into further clinical development in multiple HER2 mutant tumor types, both as monotherapy and in novel combinations."

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidatesPB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. The Company believes that neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types that over-express or have a mutation in HER2. Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements, including statements regarding the development of the Companys drug candidates. All forward-looking statements included in this press release involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has no product revenue and no products approved for marketing; the Company's dependence on PB272, which is still under development and may never receive regulatory approval; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Company's drug candidate claims; even if approved, the risk that physicians and patients may not accept or use the Company's products; the Company's reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates; the Company's dependence on licensed intellectual property; and the other risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Company's Annual Report on Form 10-K for the year ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Read more:
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non ... - Business Wire (press release)

Posted in Biotechnology | Comments Off on Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non … – Business Wire (press release)

Cellect Biotechnology (APOP) Granted European Patents Protecting Technology in Multiple Indications – StreetInsider.com

Posted: April 3, 2017 at 6:47 am

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here. (Updated - April 3, 2017 6:06 AM EDT)

Cellect Biotechnology Ltd. (NASDAQ: APOP) announced today that it has received a formal notice of Intention to Grant for a patent (Application No. 11751949.6-1466) covering a key method of treatment from the European Patent Office. The allowed claims relate to the engineering of regulatory immune cells with enhanced apoptotic activity to be used for immunomodulation in treating or preventing immune-related disorders.

Earlier this year, Cellect received a Notice of Allowance from the U.S. Patent & Trademark Office for the same patent.

The patent is expected to protect Cellects technology and method when used to treat multiple medical conditions with significant unmet needs, such as diabetes, inflammatory bowel disease, graft-versus-host disease and transplant rejection. The patent covers a segment of cell-based therapeutics that is separate from the one Cellect is currently working in, is relevant to the fast-growing class of immune therapies and Cellect believes may create an opportunity to enhance Cellects pipeline.

Shai Yarkoni, Cellects CEO, commented, Now covering both the U.S. and the EU, this patent is a base for the future commercialization of our global business. Cellect has seven families of patents and patent applications to protect its core assets for enabling stem cell regenerative medicine. With this patent, Cellect has the opportunity to diversify its pipeline and open up new commercialization routes for additional market segments.

Follow this link:
Cellect Biotechnology (APOP) Granted European Patents Protecting Technology in Multiple Indications - StreetInsider.com

Posted in Biotechnology | Comments Off on Cellect Biotechnology (APOP) Granted European Patents Protecting Technology in Multiple Indications – StreetInsider.com

The risks of unproven stem cell treatments – Radio New Zealand

Posted: April 3, 2017 at 6:47 am

An expert in stem cell treatment is warning of dodgy operators in New Zealand offering unproven and potentially dangerous treatments.

Auckland University Medical School lecturerBronwen Connor's warning comesafter arecently-released scientific paper documented a case of three women in the United States who were blinded by an experimental treatment for macular degeneration.

She said many people had stem cell therapy in the belief it was scientifically valid, but that was not often the case.

Dr Connor told Nine To Noon the cells used most often for the treatments were known as adipose cells, which were obtained from fat tissue in the body. They were popular because they couldbe obtained from a patientby liposuction, isolated out, then re-injected for supposed therapeutic use.

"Adipose stem cells obviously have a very important job, but predominantly their job is to make bone and cartilage. They also do have some anti-inflammatory properties. But they, to date, have not been shown to have any potential or ability to generate brain cells, for example, or new kidney cells or heart cells."

Websites for clinics offering the treatments listed up to 20 or 30 different types of diseases, disorders or conditions that one source of cells could supposedly treat. That was worrying, she said.

Adipose stem cells might be the right choice to help repair cartilage damage in the knee. "However, it wouldn't be your stem cell choice if you ... had Parkinson's disease and you were going to try and replace some of those lost cells in your brain."

Dr Connor said people needed to be sceptical and check if, for example, there hadbeen any human clinical trials involving the treatment.

"There are always dangers around treatments that we haven't taken out long-term and which there haven't been sufficient rigorous human clinical trials undertaken [on]. This is the purpose of clinical trials, to see what is the safety aspect and the efficacy of this procedure."

She advisedpeople to think about it in terms of medicines and drugs that people were used to taking, like aspirin. "If you inject yourself with a stem cell population and you have a bad side effect, you can't get those cells out. So ... we really need to know what those cells are going to do long-term and what any potential risk is, because they cannot be retrieved."

The Ministry of Health did not regulate stem cell therapy in this country because the cells were not regarded as medicine. She said it was a grey area, because cells were being taken from a patient and re-injected into the same patient with their consent. "But really, moving forward in the next 10 to 20 years, we're going to see more and more of these type of therapies that don't involve a pill or a tablet or our traditional thought of a medicine, and we really need to get regulations around that type of therapy."

She had spoken to people who paid large sums of money for the treatments.

"When I questioned them a little bit more ... did it help, they would sort of sheepishly say 'well, no not really'."

Dr Connor said clinics offering the treatments often emphasised the benefits according to the scientific literature, but it might be benefits in animals - not from human trials. She wanted quality control addressed and standardisedprocedures, along with safety and efficacy.

Dr Connor wanted to see clinical trials of many of the therapies,as they hadpotential. "Our fear is that, as with the three women with the macular degeneration, is that anything that goes wrong will really hinder the field because people will just see it as stem cell therapy."

Excerpt from:
The risks of unproven stem cell treatments - Radio New Zealand

Posted in Cell Medicine | Comments Off on The risks of unproven stem cell treatments – Radio New Zealand

Cord Blood Association Names STEM CELLS Translational … – Benzinga

Posted: April 3, 2017 at 6:47 am

AlphaMed Press and the Cord Blood Association (CBA) are pleased to announce that STEM CELLS Translational Medicine (SCTM) is now the association's official journal.

Durham, NC (PRWEB) March 31, 2017

AlphaMed Press and the Cord Blood Association (CBA) are pleased to announce that STEM CELLS Translational Medicine (SCTM) is now the association's official journal. With this partnership, SCTM will launch a new journal section dedicated to cord blood research.

"We are delighted to initiate this partnership with the Cord Blood Association," said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and Director of the Wake Forest Institute for Regenerative Medicine. "With this new journal section, SCTM further expands the scope of new research reports for our readers with the potential to accelerate progress in regenerative medicine."

CBA is an international nonprofit organization that promotes the work of the cord blood community for the purpose of saving lives, improving health, and changing medicine. The association is the first to join together public and private banks toward a common mission to advocate for cord blood use in order to expand its potentials in cell therapies and regenerative medicine, and to also jointly advocate for global regulations that will allow use of cord blood and cord tissues in medical applications.

SCTM is an international peer-reviewed journal, publishing articles focused on advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and helping speed translations of emerging lab discoveries into clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices and ultimately improve outcomes.

SCTM provides a platform for reporting the latest research on umbilical cord blood and tissue based therapies; engineering and manufacturing of cord blood immune cells; cord blood and cord tissue banking; the use of cord blood and cord tissue in regenerative medicine; and more. Under the leadership of section co-editors, Joanne Kurtzberg, MD, and Karen K. Ballen, MD, the Cord Blood section launches in early April with its first paper on the safety and feasibly of performing autologous umbilical cord blood infusions in young children with autism spectrum disorder.

"The Cord Blood Association is excited and honored to partner with Stem Cells Translational Medicine to showcase the newest and highest quality translational and clinical applications of cord blood and cord tissue based therapies," said Dr. Kurtzberg. "The mission and goals of both parties are aligned to maximize sharing of advances in these novel cell and tissue based therapies."

About Cord Blood Association: The Cord Blood Association will be an international nonprofit organization that promotes the banking and use of umbilical cord blood and related tissues for disease treatment and regenerative therapies.

About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS (http://www.StemCells.com), celebrating its 35th year, is the world's first journal devoted to this fast paced field of research. The Oncologist (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 22nd year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/04/prweb14204527.htm

The rest is here:
Cord Blood Association Names STEM CELLS Translational ... - Benzinga

Posted in Cell Medicine | Comments Off on Cord Blood Association Names STEM CELLS Translational … – Benzinga

Cellect Receives Notice of Intention to Grant from European Patent Office for Patent Protecting Company’s Technology … – GlobeNewswire (press…

Posted: April 3, 2017 at 6:47 am

April 03, 2017 06:02 ET | Source: Cellect Biotechnology Ltd.

Patent to provide coverage in both U.S. and EU

Method of treatment patent provides protection in diabetes, inflammatory bowel disease, graft-versus-host disease and transplant rejection

TEL AVIV, Israel, April 03, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq:APOP), (TASE:APOP), a developer of stem cell isolation technology, announced today that it has received a formal notice of Intention to Grant for a patent (Application No. 11751949.6-1466) covering a key method of treatment from the European Patent Office. The allowed claims relate to the engineering of regulatory immune cells with enhanced apoptotic activity to be used for immunomodulation in treating or preventing immune-related disorders.

Earlier this year, Cellect received a Notice of Allowance from the U.S. Patent & Trademark Office for the same patent.

The patent is expected to protect Cellects technology and method when used to treat multiple medical conditions with significant unmet needs, such as diabetes, inflammatory bowel disease, graft-versus-host disease and transplant rejection. The patent covers a segment of cell-based therapeutics that is separate from the one Cellect is currently working in, is relevant to the fast-growing class of immune therapies and Cellect believes may create an opportunity to enhance Cellects pipeline.

Shai Yarkoni, Cellects CEO, commented, Now covering both the U.S. and the EU, this patent is a base for the future commercialization of our global business. Cellect has seven families of patents and patent applications to protect its core assets for enabling stem cell regenerative medicine. With this patent, Cellect has the opportunity to diversify its pipeline and open up new commercialization routes for additional market segments.

About Cellect Biotechnology Ltd.

Cellect Biotechnology is traded on both the NASDAQ and Tel Aviv Stock Exchange (NASDAQ: "APOP", "APOPW", TASE: "APOP"). The Company has developed a breakthrough technology for the isolation of stem cells from any given tissue, a technology that aims to improve a variety of stem cells applications.

The Companys technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells in quantity and quality that will allow stem cells related treatments and procedures. Cellects technology is applicable to a wide variety of stem cells related treatments in regenerative medicine and that current clinical trials are aimed at the cancer treatment of bone marrow transplantations.

Forward Looking Statements This press release contains forward-looking statements about the Companys expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as believe, expect, intend, plan, may, should, could, might, seek, target, will, project, forecast, continue or anticipate or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss our expectation that the allowed patent will be issued in the EU and in the U.S., that, if approved, the patent will protect Cellects technology and method when used to treat multiple medical conditions with significant unmet needs, such as diabetes, inflammatory bowel disease, graft-versus-host disease and transplant rejection, that the patent may create an opportunity to enhance Cellects pipeline, may serve as a base for the potential future commercialization of Cellects global business and may provide an opportunity to diversify Cellects pipeline and potentially open up new commercialization routes for additional market segments and that Cellects technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells in quantity and quality that will allow stem cells related treatments and procedures. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading Risk Factors in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov and in the Companys period filings with the SEC and the Tel-Aviv Stock Exchange.

Related Articles

Cellect Biotechnology Ltd.

Kfar Saba, ISRAEL

http://cellectbio.com

Cellect Biotechnology Ltd. Logo

LOGO URL | Copy the link below

Formats available:

More:
Cellect Receives Notice of Intention to Grant from European Patent Office for Patent Protecting Company's Technology ... - GlobeNewswire (press...

Posted in Cell Medicine | Comments Off on Cellect Receives Notice of Intention to Grant from European Patent Office for Patent Protecting Company’s Technology … – GlobeNewswire (press…

Premier Wellness Group Offers Regenerative Cell Therapy for Knee … – GlobeNewswire (press release)

Posted: April 3, 2017 at 6:46 am

April 02, 2017 10:00 ET | Source: Premier Wellness Group

CAPE CORAL, Fla., April 02, 2017 (GLOBE NEWSWIRE) -- Regenerative cell therapy offers residents a way to reduce pain and support their bodys healing process from auto accident injuries, personal injuries, and sports injuries. Painful acute and chronic injuries can be healed using amniotic stem cells. Patients can experience pain relief without drugs with regenerative cell therapy injections that use the growth factors in amniotic stem cells to stimulate healing. Regenerative cell therapy can allow patients a safe form of pain relief and reduce their reliance on pain medications. Regenerative cell therapy is available as part of a patients individualized treatment program by the medical team at Premier Wellness Group.

Regenerative stem cell therapy offers pain relief for auto accident injuries and personal injuries, such as patients dealing with shoulder pain, knee pain, and back pain. Stem cells are a powerful tool for healing. The specialized cells begin as blank cells in that they can be used to regrow any cell needed. It is possible to regrow new cells, muscle, and tissue without surgery. Uninjured stem cells are injected into a targeted area and develop into needed cells. Stem cell therapy supports the bodys own healing process, allowing patients to benefit from injury management without surgery or painkillers.

Patients do not need to worry about any reactions due to rejection, and the amniotic regenerative stem cell therapy process is the least evasive of other forms of stem cell therapy. Patients need little, if any, downtime and stem cell therapy complements chiropractic treatments, massage therapy, nutritional counseling, and corrective exercises to guide the body back into a state of wellness. Stem cell therapy can reduce inflammation, promote healing, and increase range of motion.

We are pleased to provide patients with a natural form of pain relief and rehabilitation that takes into account the bodys own ability to heal itself, said Dr. Patrick King. Regenerative cell therapy requires no surgery- only injections performed by our physician. Stem cell therapy is safe and most patients require no downtime. We invite residents suffering from pain or trauma due to a car accident injury, sports injury, or personal injury to contact our team to learn more about this advanced therapy for healing and recovery.

Dr. Patrick King, clinic director and owner of Premier Wellness Group, has served the chiropractic and rehabilitation needs of residents of Cape Coral, Fort Myers, and surrounding communities for more than 15 years. Patients have made Premier Wellness Group their destination for drug-free, non-surgical pain relief, and rehabilitation. Services at Premier Wellness Group include regenerative cell therapy, trigger point therapy, corrective exercises, lifestyle recommendations, and chiropractic care.

Call (239) 573-7988 to learn more about Cape Coral regenerative cell therapy for knee and shoulder pain relief, or to schedule an appointment. Visit http://www.mypremierwellnessgroup.com/ for additional details.

Related Articles

View original post here:
Premier Wellness Group Offers Regenerative Cell Therapy for Knee ... - GlobeNewswire (press release)

Posted in Cell Therapy | Comments Off on Premier Wellness Group Offers Regenerative Cell Therapy for Knee … – GlobeNewswire (press release)

Hingham man running 20th consecutive marathon despite diabetes – Wicked Local Hingham

Posted: April 3, 2017 at 6:45 am

Special to the Journal

Hinghams Ryan Enright was diagnosed with a unique form of diabetes, known as latent autoimmune diabetes in adults (LADA), in 2010 and this year, Enright will be running his 20th Boston Marathon for Joslin Diabetes Center, where he receives his diabetes care from Dr. Elena Toschi.

Since being diagnosed six years ago, the 44-year-old has learned how to manage and cope with his diabetes with the help of the doctors, educators and staff at Joslin, which is especially important for a seasoned marathoner.

Enright is running 40-50 miles each week in preparation for his 25th marathon, doing his long runs on the weekends in Hingham and logging miles along the Charles River during the week. He wears a continuous glucose monitor (CGM) to monitor his blood sugar levels as he runs, and has had to experiment with the settings to ensure he does not go high or low as his distances increase.

My hope is that the funds I raise will benefit Joslin and their team of researchers in their battle to find a cure, said Enright. This is a very specialyear for me given that it will be my 20th consecutive Boston Marathon and I am so grateful that I have the resources at Joslin who make it possible for me to make that left on Boylston Street and cross the finish line. Running on Team Joslin for the second year in a row has allowed me to elevate the awareness of this great organization and educate people on what diabetes is all about, and how it can be prevented and treated. I credit the education, passion and mission of Joslin for helping me not miss a step on my way to Boston number 20.

Ryans goal is to raise $10,000 for Joslins High Hopes Fund. For more information or to donate, visit Ryans CrowdRise page: https://www.crowdrise.com/JoslinDiabetesCenterBoston2017/fundraiser/ryanenright.

Read more from the original source:
Hingham man running 20th consecutive marathon despite diabetes - Wicked Local Hingham

Posted in Diabetes | Comments Off on Hingham man running 20th consecutive marathon despite diabetes – Wicked Local Hingham

Page 1,618«..1020..1,6171,6181,6191,620..1,6301,640..»